PDCD1 and acute myeloid leukemia: Several studies show that the combination of PD-1/PD-L1 mAbs is promising research, for instance, the combined blockade of PD-1 signaling and Tim-3 have an additive effect on inhibiting tumor growth in advanced AML mouse models (112).